The MADIT-ICD benefit score was a significant predictor of non-arrhythmic death (HR 1.98; 95% CI 1.23-3.20; P=0.005), helping identify suitable candidates for CRT-D among Japanese individuals.
Cohort
Yes
Does the MADIT-ICD benefit score predict ventricular arrhythmias and non-arrhythmic death in Japanese patients undergoing primary prevention cardiac resynchronization therapy?
The MADIT-ICD benefit score effectively identifies Japanese CRT patients at high risk for ventricular arrhythmias and non-arrhythmic death, aiding in the optimal selection of candidates for concurrent defibrillator therapy.
Effect estimate: HR 1.98 (95% CI 1.23-3.20)
p-value: p=0.005
BACKGROUND: Although the MADIT-ICD benefit score (MBS) helps select suitable implantable cardioverter defibrillator (ICD) candidates, optimal indicators for cardiac resynchronization therapy (CRT) remain uncertain. Evaluating the applicability of the MBS in Japanese CRT patients is imperative. METHODS AND RESULTS: (HR 1.98; 95% CI 1.23-3.20; P=0.005) were significant predictors of non-arrhythmic death. CONCLUSIONS: The MBS can identify suitable candidates for CRT-D among Japanese individuals.
Sato et al. (Fri,) conducted a cohort in Cardiac Resynchronization Therapy (CRT) patients. MADIT-ICD benefit score (MBS) was evaluated on non-arrhythmic death (HR 1.98, 95% CI 1.23-3.20, p=0.005). The MADIT-ICD benefit score was a significant predictor of non-arrhythmic death (HR 1.98; 95% CI 1.23-3.20; P=0.005), helping identify suitable candidates for CRT-D among Japanese individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: